Adam JacksonJanuary 3, 2024
The firm is targeting the FDA’s 505(b)(2) pathway for a potentially expedited approval process.
Unpack the industry with the daily cannabis newsletter for business leaders.
Unpack the industry with the daily cannabis newsletter for business leaders.